Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Austria-based biotechnology company Intercell has announced that its collaborator Merck & Co has initiated a Phase II clinical trial of V710, an investigational vaccine for the prevention of Staphylococcus aureus infections.
Subscribe to our email newsletter
This randomized double blind, placebo controlled study aims to evaluate the safety and immunogenicity of the vaccine candidate in patients with end-stage kidney disease on hemodialysis. This trial start follows the initiation of a separate Phase II trial in December 2007.
The Staphylococcus aureus vaccine candidate is based on a conserved protein antigen discovered by Intercell and licensed to Merck & Co in 2004 on an exclusive world wide basis.
Merck is responsible for clinical development, manufacturing and marketing. Intercell is eligible to receive milestone payments and royalties on future net sales.
Gerd Zettlmeissl, CEO of Intercell, said: “We are very pleased that our strategic partner Merck has chosen to initiate a further Phase II clinical trial. We look forward to continued progress of the program building on clinical data obtained so far.”